Clinical Dilemmas in Diabetes. Группа авторов

glucose monitoring systems Flash glucose monitoring systems References 8 Does HbA1c Remain the Most Important Therapeutic Target in Outpatient Management of Diabetes? The glucose hypothesis and vascular risk Measuring glycemic control in the clinical management of diabetes Additional therapeutic targets to consider for hyperglycemia in the outpatient management of diabetes Summary References 9 Technology Issues: Continuous Glucose Monitoring, Insulin Pumps, and Closed Loop Control for Patients with Diabetes Introduction Continuous Glucose Monitoring (CGM) for Diabetes Care Currently Approved CLC for T1DM Post‐marketing Studies Ongoing Pivotal Studies/Anticipated Closed Loop System Closed Loop Control Initiation at Onset of T1D CLC is Being Tested in Specific Subgroups with Type 1 Diabetes at Present Cost of Diabetes Technologies Insulin Pump Use for People With T2DM Conclusion References 10 Optimizing Diet in Patients with Diabetes Summary References 11 Are Insulin Sensitizers Useful Additions to Insulin Therapy? Insulin sensitizers Biguanides Thiazolidinediones Discussion References 12 Incretin‐Based Therapy for the Management of Type 2 Diabetes Introduction The incretin effect Early development of GLP‐1 RA therapy Clinical benefits and side effects of GLP‐1 RAs The evidence for GLP‐1 ras in management of type 2 diabetes The role of DPP‐4 inhibitors in type 2 diabetes management Cardiovascular outcomes with incretin‐based therapies for type 2 diabetes Incorporating incretin‐based therapy into clinical practice Conclusions Key points References

      8  PART III: Diagnosis and Management of Cardiovascular Risk Factors and Cardiovascular Disease 13 Screening Patients with Prediabetes and Diabetes for Cardiovascular Disease Introduction Guidelines Hyperglycemia and risks of CVD Traditional risk factors Diabetes‐specific clinical risk predictors of CVD Nontraditional risk factors Screening tools Risk calculators Summary References 14 Choosing Medications for Type 2 Diabetes – What Weighting Should Be Given to Cardiovascular Risk Reduction? Diabetes and cardiovascular risk: how does it affect therapeutic goals? Metformin Sulfonylureas Thiazolidinediones Acarbose Colesevelam Pramlintide Bromocriptine Glucagon‐like peptide‐1‐based therapy SGLT‐2i Conclusions References 15 Choosing Medications for Weight Loss in Type 2 Diabetes Mellitus Introduction: Prevalence and relationship of obesity and type 2 diabetes Therapeutic classes for the treatment of type 2 Diabetes and their effects on weight Use of diabetic medications for weight loss in patients without diabetes A Practical Guide to Choosing medication for type 2 diabetes with weight loss in mind References 16 Are